Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg
Launched by DONG-A ST CO., LTD. · Apr 25, 2016
Trial Information
Current as of September 06, 2025
Completed
Keywords
ClinConnect Summary
A randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence, crossover study
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy Male Volunteers (Age: 19\~45years)
- • 55\<Body Weight\<90, 18\<BMI\<27
- • FPG: 70-125 mg/dL
- Exclusion Criteria:
- • galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
- • Clinically significant Medical History
- • Allergy or Drug Hypersensitivity
- • AST(SGOT), ALT(SGPT) \> Upper Normal Range\*1.5, eGFR\<80 mL/min
- • Drink during clinical trial period
- • Smoking during clinical trial period
- • Grapefruit/Caffeine intake during clinical trial period
- • No Contraception
About Dong A St Co., Ltd.
Dong-A ST Co., Ltd. is a leading pharmaceutical and biotechnology company based in South Korea, dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a robust portfolio spanning various therapeutic areas, including neurology, oncology, and cardiovascular health, Dong-A ST is committed to advancing healthcare through cutting-edge clinical research and high-quality products. The company emphasizes a patient-centered approach, collaborating with global partners to enhance treatment options and improve health outcomes worldwide. Through its rigorous clinical trials and commitment to scientific excellence, Dong-A ST strives to contribute meaningfully to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Kyung-Sang Yu, M.D., Ph.D.
Principal Investigator
Clinical Trials Center, Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials